ArticleJournal of healthcare engineering2022
Psoriasis Vulgaris of Blood Heat Syndrome in Plasma Based on Widely Targeted Techniques.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional Chinese medicine classifies psoriasis (Ps) according to clinical manifestations, and its different clinical manifestations imply the pathogenesis and material evolution basis of Ps, especially biomarkers that are meaningful to identification of Ps, treatment response, and elucidation of the pathogenesis of the disease. This study aims to screen differential metabolites in plasma of psoriasis vulgaris (PV) of blood heat syndrome based on a widely targeted metabolomic technique and to analyze syndrome metabolic markers and metabolic pathways. Forty-five PV patients were recruited, including 21 cases of the blood heat syndrome group (BH-PPG), 24 cases of the non-blood-heat syndrome group (NBH-PPG), and 30 healthy cases of the normal control group (NPG). The UPLC-MS/MS detection platform, a self-developed database, and multivariate statistical analysis were applied to investigate the plasma metabolic differences. The biomarkers related to blood heat syndrome were screened using the principal component analysis method. A total of 479 metabolites were detected in the three groups of plasma samples; 72 different metabolites were sorted out in the BH-PPG/NPG group, 82 in the NBH-PPG/NPG group, and 8 in the BH-PPG/NBH-PPG group. Differential metabolites mainly consist of metabolites of organic acids, amino acids, carbohydrates, and nucleotides. Multiple metabolites ginkgolic acid, pyrroloquinoline quinone, L-aspartic acid, and citramalic acid were expected to be the potential biomarkers of blood heat syndrome PV. The formation and evolution processes may be associated with disorders and regulation of metabolic pathways, ferroptosis, carbon metabolism, and purine metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.